Amgen spent years bracing for biosimilar and generic competition to its top-selling meds, but now its own biosimilars are kicking in sales to help fill those patent-cliff gaps. Those copycats—including biosims to Roche’s cancer blockbusters—delivered $173 million to soften its patent-cliff
read morePfizer is reshaping itself to focus on innovative drugs and that effort will allow it to turn in strong growth for years, execs said Tuesday. The drugmaker predicts it’ll generate 6% annual revenue growth over the next five years, outperforming
read moreLast July, Pfizer decided to reorganize and lumped off-patent drugs into an autonomous unit. A month later, Mylan launched a strategic review to appease restive shareholders. Once the two companies realized they had common ground—and Pfizer CEO Albert Bourla made
read moreWhen Mylan and Pfizer’s Upjohn business trumpeted their merger in July, it marked a major coup for the generics maker’s shareholders after a rough couple of years. Turns out the deal wasn’t just profitable for Mylan’s investors—it was also a
read moreMerck’s immuno-oncology blockbuster Keytruda rose 62% in the third quarter, and the product remains a a key player in the company’s short- and long-term pipeline. But Wall Street analysts are pressing the company for details about whether the drug can
read moreNASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function. More: Gilead, Glympse Bio to explore biomarker use in NASH Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals